

PRESS RELEASE

Lund - 23 June 2011



Bo Håkansson increases ownership in Hansa Medical AB (publ) through acquisition of more than 1 million shares

Bo Håkansson has acquired 1,038,609 shares in Hansa Medical AB (publ) through his fully owned company Farstorp Invest AB. The acquisition corresponds to approximately 8 % of votes and capital in Hansa Medical. Following the acquisition and the recently accomplished rights issue, Bo Håkansson via company holds 53,6% of votes and capital in Hansa Medical.

For further information, please contact:

Hansa Medical AB
Emanuel Björne, CEO
Mobile: +46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

ABOUT HANSA MEDICAL

Hansa Medical is a biotechnology research and development company focused on the treatment and diagnosis of inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, anti-alpha-11 and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. Hansa Medical is listed on NASDAQ OMX First North, and Remium AB is the company's Certified Adviser.

Hansa Medical AB
P.O. Box 785
SE-220 07 Lund
Telephone +46 46 16 56 70
Fax +46 46 12 77 75
info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Scheelevägen 22
Lund